AIM ImmunoTech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AIM ImmunoTech and other ETFs, options, and stocks.

About AIM

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. 

CEO
Thomas Kenwood Equels
CEOThomas Kenwood Equels
Employees
23
Employees23
Headquarters
Ocala, Florida
HeadquartersOcala, Florida
Founded
1966
Founded1966
Employees
23
Employees23

AIM Key Statistics

Market cap
2.95M
Market cap2.95M
Price-Earnings ratio
-0.03
Price-Earnings ratio-0.03
Dividend yield
Dividend yield
Average volume
245.94K
Average volume245.94K
High today
$0.699
High today$0.699
Low today
$0.69
Low today$0.69
Open price
$0.6979
Open price$0.6979
Volume
7.94K
Volume7.94K
52 Week high
$35.96
52 Week high$35.96
52 Week low
$0.6675
52 Week low$0.6675

Stock Snapshot

The current AIM ImmunoTech(AIM) stock price is $0.70, with a market capitalization of 2.95M. The stock trades at a price-to-earnings (P/E) ratio of -0.03.

As of 2026-03-05, AIM ImmunoTech(AIM) stock has fluctuated between $0.69 and $0.70. The current price stands at $0.70, placing the stock +1.1% above today's low and -0.2% off the high.

AIM ImmunoTech(AIM) shares are trading with a volume of 7.94K, against a daily average of 245.94K.

During the past year, AIM ImmunoTech(AIM) stock moved between $0.67 at its lowest and $35.96 at its peak.

During the past year, AIM ImmunoTech(AIM) stock moved between $0.67 at its lowest and $35.96 at its peak.

AIM News

TipRanks 23h
Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: AIM Immunotech (...

TipRanks 1d
AIM ImmunoTech announces preliminary results of rights offering

AIM ImmunoTech (AIM) announced the preliminary results of its previously announced rights offering which expired at 5:00 p.m., Eastern Time, on March 3, 2026. T...

TipRanks 3d
AIM ImmunoTech signs agreement for planning of Phase 3 trial of Ampligen

AIM ImmunoTech (AIM) announced an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design AIM’s anticipated Phase 3 clinic...

People also own

Based on the portfolios of people who own AIM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.